Evidence supporting the use of: Acetyl l-carnitine
For the health condition: Nerve Damage

Links: Go back one page, Tool main page, Ingredients list, Health conditions list, Body systems list

Synopsis

Source of validity: Scientific
Rating (out of 5): 3

Acetyl L-carnitine (ALC) has scientific evidence supporting its use in treating certain forms of nerve damage, particularly peripheral neuropathy. Several clinical trials and meta-analyses have shown that ALC supplementation may help reduce pain and improve nerve regeneration in patients with diabetic neuropathy, chemotherapy-induced neuropathy, and other peripheral nerve disorders. The proposed mechanisms include enhancing mitochondrial energy production, reducing oxidative stress, and promoting nerve growth factor expression, all of which may facilitate nerve repair and function.

A 2005 double-blind, placebo-controlled trial published in Diabetes Care found that ALC improved both subjective pain symptoms and objective nerve conduction velocities in diabetic patients. Subsequent meta-analyses have confirmed modest benefits, particularly in pain reduction. There is also evidence suggesting that ALC might aid recovery in cases of nerve injury and may offer neuroprotective effects, though results across studies are somewhat variable. It is generally well tolerated, with few side effects reported.

While ALC is not considered a first-line therapy for neuropathy, it is sometimes recommended as an adjunct to standard treatments, especially when conventional medications are ineffective or not tolerated. Overall, the evidence base is moderate (rated 3/5), with more high-quality, large-scale trials needed to clarify which patient populations benefit most and to establish optimal dosing regimens.

More about acetyl l-carnitine
More about Nerve Damage